STOCKHOLM — Trial results are demonstrating the safety and effectiveness of a novel gene modifier therapy for treating retinitis pigmentosa associated with NR2E3 and RHO mutations. Researchers ...
Adelaide University researchers have carried out the first in-human trial of a new type of treatment for a leading cause of ...
Adelaide University researchers have carried out the first in-human trial of a new type of treatment for a leading cause of ...
Retinitis pigmentosa retinal degeneration is caused by a family of hereditary mutations in nearly 100 genes that slowly lead to blindness over years or decades. One of those genes encodes the enzyme ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
Scientists have identified two non-retinoid compounds that may be able to treat retinitis pigmentosa (RP), a group of inherited eye diseases that cause blindness. The compounds were discovered by ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
Treatment with bioavailable small-molecule pharmacochaperones targeting the visual receptor rhodopsin offers a promising approach to prevent retinal photoreceptor degeneration caused by inherited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results